Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor
To the Editor.—We conducted an analysis
to model the potential economic impact of making triple-drug antiretroviral
therapy widely available to persons with human immunodeficiency virus (HIV)
in selected countries within the Americas.
Model parameters were based, where possible, on empirical data and published
research. Based on the percentage of adults who are HIV-positive in the province
of British Columbia and treated with antiretroviral therapy in 1997, we assumed
that over the course of 1 year 25% of the HIV-positive population would be
eligible for therapy. Triple-drug costs were based on average costs of 2 nucleosides
(lamivudine plus zidovudine or stavudine) with a protease inhibitor (ritonavir,
indinavir, or saquinavir) over the course of 12 months in British Columbia.
National seroprevalence levels as of the end of 1994 were reported by the
World Health Organization.1 Population and
gross national product (GNP) estimates for 1995 were taken from the World Development Report.2
Montaner JSG, Hogg RS, Weber AE, Anis AH, O'Shaughnessy MV, Schechter MT. The Costs of Triple-Drug Anti-HIV Therapy for Adults in the Americas. JAMA. 1998;279(16):1263-1264. doi:10.1001/jama.279.16.1259